<div id="readability-page-1"><p>Inspire Investing LLC boosted its holdings in shares of  Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 125.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 72,459 shares of the biotechnology company's stock after buying an additional 40,386 shares during the period. Inspire Investing LLC's holdings in Exelixis were worth $2,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>3 Stocks to Buy for a Soft Landing, If There Is One</li></ul><p>Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Byrne Asset Management LLC grew its stake in shares of  Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 400 shares during the last quarter.  Luminist Capital LLC boosted its stake in  Exelixis by 2,740.0% in the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 685 shares in the last quarter.  Family Legacy Financial Solutions LLC purchased a new stake in  Exelixis during the 2nd quarter worth approximately $33,000.  Steph &amp; Co. purchased a new stake in  Exelixis during the 2nd quarter worth approximately $44,000.  Finally, Hantz Financial Services Inc. increased its stake in  Exelixis by 940.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 1,025 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Exelixis Stock Up 0.1%</h2><p>EXEL stock opened at $46.64 on Thursday. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62. The firm has a market cap of $12.50 billion, a P/E ratio of 19.68, a PEG ratio of 0.84 and a beta of 0.40. The company's 50-day simple moving average is $41.53 and its 200-day simple moving average is $40.88. </p><ul><li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li></ul><p>Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company had revenue of $597.76 million during the quarter, compared to analysts' expectations of $590.04 million. During the same quarter in the prior year, the firm posted $0.47 EPS. Exelixis's quarterly revenue was up 10.8% compared to the same quarter last year.  On average, analysts anticipate that  Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In other Exelixis news, EVP Dana Aftab sold 48,383 shares of the company's stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the transaction, the executive vice president directly owned 664,778 shares in the company, valued at approximately $28,253,065. This represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the sale, the director owned 1,189,228 shares in the company, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 245,235 shares of company stock worth $10,490,600. Corporate insiders own  2.82% of the company's stock. </p><h2>Analyst Ratings Changes</h2><ul><li>7 Best Cancer Stocks to Invest in Now</li></ul><p>Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price objective on shares of Exelixis from $46.00 to $49.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, November 5th. UBS Group lifted their price target on Exelixis from $35.00 to $40.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Leerink Partners raised Exelixis from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $48.00 price objective on the stock in a report on Tuesday, October 21st. Wells Fargo &amp; Company decreased their target price on Exelixis from $36.00 to $30.00 and set an &#34;equal weight&#34; rating for the company in a report on Tuesday, October 21st. Finally, TD Cowen upped their target price on Exelixis from $44.00 to $51.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. One investment analyst  has rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating and eleven have assigned  a Hold rating to the stock. According to data from MarketBeat.com, Exelixis  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.74.</p><p><b>View Our Latest Stock Analysis on EXEL</b></p><h2>About Exelixis</h2> (Free Report)<p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.  </p><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Exelixis</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exelixis Right Now?</h2><p>Before you consider Exelixis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EXEL

<p>Inspire Investing LLC increased its holdings in Exelixis, Inc. by 125.9% in Q3, now owning 72,459 shares worth $2,993,000. Other institutional investors also adjusted their stakes. Exelixis reported Q3 earnings of $0.78 per share, beating estimates, with revenue up 10.8% year-over-year. Insiders sold 245,235 shares worth $10,490,600 last quarter. Analysts have mixed ratings, with some raising price targets.</p>

Exelixis, Inc. $EXEL Shares Purchased by Inspire Investing LLC